Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENRICH Ibrutinib for untreated mantle cell lymphoma
ISRCTN11038174Phase 3Active, not recruiting
- Sponsor
- University Hospitals Plymouth
- Start
- Nov 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of ibrutinib, rituximab, cyclophosphamide, doxorubicin, vincristine and 2 more in mantle cell lymphoma (MCL) (2 arms), sponsored by University Hospitals Plymouth. Primary endpoint: Progression-free survival. Started Nov 2015; status: active, not recruiting.
02
Drugs
ibrutinibrituximabcyclophosphamidedoxorubicinvincristine
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on ISRCTN11038174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN11038174.